In “Ebolanomics,” James Surowiecki writes for The New Yorker about why we don’t have an ebola vaccine yet. In short, because there aren’t enough (rich) people in developed countries who need it, so the pharmaceutical companies have no incentive to develop it. Or, no financial incentive, which is the only real incentive there is.
Ebola may or may not effect you, but the pending resistance to antibiotics sure might! And the same rules apply. Sure, lots of people with money need antibiotics and would be willing to pay for them. But we’d have to limit the use of a new antibiotic in order to maintain effectiveness, so by their nature, antibiotics limit return on research investment. Guess we’ll all just die instead.
But wait! There is some hope.